JP5909442B2 - ヒト化ａｘｌ抗体 - Google Patents

ヒト化ａｘｌ抗体 Download PDF

Info

Publication number
JP5909442B2
JP5909442B2 JP2012510274A JP2012510274A JP5909442B2 JP 5909442 B2 JP5909442 B2 JP 5909442B2 JP 2012510274 A JP2012510274 A JP 2012510274A JP 2012510274 A JP2012510274 A JP 2012510274A JP 5909442 B2 JP5909442 B2 JP 5909442B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
axl
acid sequence
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012510274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526530A5 (https=
JP2012526530A (ja
Inventor
ペーター・ヴィルツ
イェンス・ルーエ
剛 滝沢
剛 滝沢
知子 高山
知子 高山
Original Assignee
ユー３・ファーマ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by ユー３・ファーマ・ゲーエムベーハー filed Critical ユー３・ファーマ・ゲーエムベーハー
Publication of JP2012526530A publication Critical patent/JP2012526530A/ja
Publication of JP2012526530A5 publication Critical patent/JP2012526530A5/ja
Application granted granted Critical
Publication of JP5909442B2 publication Critical patent/JP5909442B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012510274A 2009-05-11 2010-05-11 ヒト化ａｘｌ抗体 Expired - Fee Related JP5909442B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006355.3 2009-05-11
EP09006474 2009-05-13
EP09006474.2 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015188556A Division JP2016011306A (ja) 2009-05-11 2015-09-25 ヒト化ａｘｌ抗体

Publications (3)

Publication Number Publication Date
JP2012526530A JP2012526530A (ja) 2012-11-01
JP2012526530A5 JP2012526530A5 (https=) 2013-06-20
JP5909442B2 true JP5909442B2 (ja) 2016-04-26

Family

ID=42272537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012510274A Expired - Fee Related JP5909442B2 (ja) 2009-05-11 2010-05-11 ヒト化ａｘｌ抗体
JP2015188556A Pending JP2016011306A (ja) 2009-05-11 2015-09-25 ヒト化ａｘｌ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015188556A Pending JP2016011306A (ja) 2009-05-11 2015-09-25 ヒト化ａｘｌ抗体

Country Status (15)

Country Link
US (2) US8841424B2 (https=)
EP (1) EP2430050A1 (https=)
JP (2) JP5909442B2 (https=)
KR (1) KR20120035145A (https=)
CN (1) CN102421802B (https=)
AR (1) AR076564A1 (https=)
AU (1) AU2010247464B2 (https=)
BR (1) BRPI1013428A2 (https=)
CA (1) CA2759836A1 (https=)
IL (1) IL216147A (https=)
MX (1) MX2011011825A (https=)
RU (2) RU2571224C2 (https=)
TW (2) TWI526223B (https=)
WO (1) WO2010130751A1 (https=)
ZA (1) ZA201107529B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016011306A (ja) * 2009-05-11 2016-01-21 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
CA2839508A1 (en) * 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
ES2677367T3 (es) * 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
PL2914630T3 (pl) * 2012-11-05 2021-09-06 Pierre Fabre Médicament Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
CA2894539C (en) * 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
JP6864953B2 (ja) * 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
EP4679095A3 (en) 2015-05-18 2026-05-06 Agensys, Inc. Antibodies that bind to axl proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
PL3319993T3 (pl) 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
DK3354729T5 (da) 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
SMT202600033T1 (it) * 2016-04-15 2026-03-09 Bioatla Inc Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
US11807688B2 (en) * 2020-02-28 2023-11-07 Les Laboratoires Servier Anti-AXL antibodies and compositions
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
EP4132652A1 (en) 2020-04-08 2023-02-15 BerGenBio ASA Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
AU5597500A (en) 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
CA2692320A1 (en) 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
EP2219671A4 (en) * 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
JP5769969B2 (ja) * 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
CA2759836A1 (en) * 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016011306A (ja) * 2009-05-11 2016-01-21 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体

Also Published As

Publication number Publication date
ZA201107529B (en) 2012-06-27
US20150037323A1 (en) 2015-02-05
AU2010247464B2 (en) 2014-09-11
WO2010130751A1 (en) 2010-11-18
EP2430050A1 (en) 2012-03-21
AU2010247464A1 (en) 2011-11-10
IL216147A0 (en) 2012-01-31
AR076564A1 (es) 2011-06-22
KR20120035145A (ko) 2012-04-13
TWI526223B (zh) 2016-03-21
RU2015147287A (ru) 2017-05-12
JP2016011306A (ja) 2016-01-21
CN102421802A (zh) 2012-04-18
TW201509431A (zh) 2015-03-16
TW201105348A (en) 2011-02-16
US8841424B2 (en) 2014-09-23
BRPI1013428A2 (pt) 2019-07-02
IL216147A (en) 2016-04-21
JP2012526530A (ja) 2012-11-01
US20120117670A1 (en) 2012-05-10
MX2011011825A (es) 2011-12-06
CA2759836A1 (en) 2010-11-18
RU2571224C2 (ru) 2015-12-20
CN102421802B (zh) 2014-08-20
RU2011150183A (ru) 2013-06-20

Similar Documents

Publication Publication Date Title
JP5909442B2 (ja) ヒト化ａｘｌ抗体
JP5769969B2 (ja) Ａｘｌ抗体
JP2011505120A5 (https=)
CN108383909A (zh) 抗sez6抗体及使用方法
CN111253488A (zh) Cd47抗体及其制备方法和应用
CN111196854A (zh) Ox40抗体及其制备方法和应用
KR20240052881A (ko) Pmel17에 대한 항체 및 이의 접합체
EP2270053A1 (en) Humanized AXL antibodies
JP2024535851A (ja) Ｄ３結合分子及びその使用
TW202210518A (zh) 結合人cd38的抗體、其製備方法和用途
US20150152193A1 (en) Axl antibodies
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
HK1185622B (zh) Axl抗体
HK1147275B (en) Axl antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160229

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160328

R150 Certificate of patent or registration of utility model

Ref document number: 5909442

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees